Vitality Watch

Dossier pubmed preclinical 10-sep-2026
Animal model, organoid, or cell-culture result — not yet human

Mitochondria-targeted esculetin mitigates age-associated cardiac remodeling through coordinated activation of AMPK-SIRT1 and inhibition of p38 MAPK signaling.

Key claim: Mitochondria-targeted esculetin (Mito-Esc) attenuates age- and hypercholesterolemia-associated cardiac hypertrophy, fibrosis, inflammation, and senescence in ApoE mice and cardiomyocytes via AMPK–SIRT1 activation and p38 MAPK inhibition, with effects comparable to metformin.

Abstract

Age-associated cardiac remodeling, characterized by hypertrophy and fibrosis, is a major contributor to cardiovascular morbidity in the elderly and is often exacerbated by metabolic stressors such as hypercholesterolemia. Given the central role of mitochondrial dysfunction in these processes, we investigated whether mitochondria-targeted esculetin (Mito-Esc) could mitigate pathological cardiac remodeling associated with aging and hypercholesterolemia. To model this condition, we utilized 12-month-old Apoemice, which exhibit chronic hypercholesterolemia and develop age-related cardio-metabolic structural alterations. The efficacy of Mito-Esc was compared with metformin, a putative geroprotective agent. Treatment with Mito-Esc or metformin significantly attenuated cardiac hypertrophy, fibrosis, inflammation, and oxidative stress in aged Apoemice. These protective effects were further validated in vitro using H9c2 cardiomyocytes and primary adult mouse cardiac fibroblasts. Mechanistically, both Mito-Esc and metformin exerted cardioprotective effects through activation of the AMPK-SIRT1 signaling axis. Depletion of either AMPK or SIRT1 markedly reduced the ability of these compounds to suppress cellular senescence, hypertrophic responses, and fibrotic signaling, indicating a critical role for this pathway. AMPK functioned upstream of SIRT1, as SIRT1 activation was attenuated following AMPK depletion. In parallel, both compounds significantly suppressed p38 MAPK activation. While depletion of AMPK or SIRT1 did not affect p38 MAPK activity, pharmacological inhibition of p38 MAPK enhanced AMPK and SIRT1 activation, supporting a model in which p38 MAPK activation negatively regulates the AMPK-SIRT1 axis. Collectively, these findings demonstrate that Mito-Esc alleviates pathological cardiac remodeling in the setting of aging and hypercholesterolemia through coordinated activation of AMPK-SIRT1 signaling and inhibition of p38 MAPK.

Why this matters

Coumarin-based mitochondria-targeted small molecules keep expanding the preclinical toolkit for engaging the AMPK–SIRT1 arm of nutrient sensing directly at the organelle, and cardiac remodeling is one of the tissue contexts where that arm plausibly bridges mitochondrial dysfunction, senescence, and inflammaging. The finding matters less as new pathway biology — AMPK–SIRT1 up, p38 MAPK down is a familiar template — and more as another aged-mammal in vivo instance where a mito-targeted compound reproduces a metformin-like cardiac phenotype without human data.

Source

Link

Briefing card

Mitochondria-targeted esculetin mitigates age-associated cardiac remodeling through coordinated activation of AMPK-SIRT1 and inhibition of p38 MAPK signaling.
Stage: preclinical · pubmed · 10-sep-2026

If you follow mitochondria-targeted geroprotector candidates, Mito-Esc now has aged-mouse cardiac data comparable to metformin — but no human trials exist.

Mitochondria-targeted esculetin (Mito-Esc) attenuates age- and hypercholesterolemia-associated cardiac hypertrophy, fibrosis, inflammation, and senescence in ApoE mice and cardiomyocytes via AMPK–SIRT1 activation and p38 MAPK inhibition, with effects comparable to metformin.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1016/j.bbrc.2026.154568

build build 880 · 2bcef25 · 2026-11-18